Coherus Oncology, Inc. (CHRS) Reports 89% cORR in 1L ESCC Interim Data

Coherus Oncology reported interim phase 1b trial results showing tagmokitug, combined with Loqtorzi and chemotherapy, achieved a 75% overall response rate in esophageal cancer patients as a first-line therapy, regardless of PD-L1 status, according to the company.

Coherus Oncology (CHRS) shares rose more than 15% after the company announced a special dividend of contingent value rights (CVRs) tied to monetizing remaining biosimilar assets. CVRs will be distributed pro rata to stockholders of record Sept. 30, 2026, with distribution scheduled for Oct. 7, 2026. Coherus reported Q2 2026 net loss from continuing ops of $33.3M and LOQTORZI revenue up 37% to $13.6M.

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with emerging evidence of activity with tagmokit

Coherus Oncology and Zumutor Biologics said they will collaborate on a Phase 1 trial combining ZM008, an NK checkpoint anti-LLT1 antibody, with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor. The study will enroll up to 45 patients in the U.S. across dose-escalation and expansion cohorts for several solid tumors, including CRC, HNSCC, NSCLC, ccRCC and urothelial cancers.